These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26762749)

  • 1. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment.
    Ham JS; Kim S; Kim HK; Byeon S; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Han J; Park W; Ahn MJ
    J Thorac Oncol; 2016 Jan; 11(1):e1-4. PubMed ID: 26762749
    [No Abstract]   [Full Text] [Related]  

  • 2. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
    Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
    Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
    Bersanelli M; Minari R; Bordi P; Gnetti L; Bozzetti C; Squadrilli A; Lagrasta CA; Bottarelli L; Osipova G; Capelletto E; Mor M; Tiseo M
    J Thorac Oncol; 2016 Oct; 11(10):e121-3. PubMed ID: 27257132
    [No Abstract]   [Full Text] [Related]  

  • 4. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
    Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC
    Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?
    Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ
    Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
    Remon J; Planchard D
    Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.
    Schmid S; Stewart EL; Martins-Filho SN; Cabanero M; Wang A; Bao H; Wu X; Patel D; Chen Z; Law JH; Bradbury PA; Shepherd FA; Leighl N; Tsao MS; Pugh T; Bratman SV; Sacher A; Liu G
    Clin Lung Cancer; 2020 Sep; 21(5):e488-e492. PubMed ID: 32389504
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.
    Piotrowska Z; Drapkin B; Engelman JA; Nagy RJ; Lanman RB; Sequist LV
    J Thorac Oncol; 2016 Aug; 11(8):e95-e97. PubMed ID: 27079185
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.
    Grolleau E; Haddad V; Boissière L; Falchero L; Arpin D
    J Thorac Oncol; 2019 Jul; 14(7):e151-e153. PubMed ID: 31235042
    [No Abstract]   [Full Text] [Related]  

  • 10. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.
    Chiang CL; Yeh YC; Chou TY; Chiu CH
    J Formos Med Assoc; 2020 Sep; 119(9):1439-1441. PubMed ID: 32173232
    [No Abstract]   [Full Text] [Related]  

  • 11. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
    Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
    Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Changes and Drug-Induced Selection of Resistant Clones in a Patient With EGFR-Mutated Adenocarcinoma That Acquired T790M Mutation and Transformed to Small-Cell Lung Cancer.
    Iijima Y; Hirotsu Y; Mochizuki H; Amemiya K; Oyama T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Miyashita Y; Omata M
    Clin Lung Cancer; 2018 Nov; 19(6):e843-e847. PubMed ID: 30122430
    [No Abstract]   [Full Text] [Related]  

  • 13. High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.
    Nanjo S; Ebi H; Arai S; Takeuchi S; Yamada T; Mochizuki S; Okada Y; Nakada M; Murakami T; Yano S
    Oncotarget; 2016 Jan; 7(4):3847-56. PubMed ID: 26716903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.
    Chen CW; Kuo CW; Chen YL; Ho CL; Su WC; Lin CC
    J Thorac Oncol; 2017 Jun; 12(6):e72-e74. PubMed ID: 28532566
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
    Okuno T; Arakawa S; Yoshida T; Ohe Y
    Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
    Yan Y; Jiang G; Ma W; Li T; Wang L
    Clin Lung Cancer; 2020 Nov; 21(6):562-567. PubMed ID: 32622727
    [No Abstract]   [Full Text] [Related]  

  • 17. Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinib.
    Haratani K; Hayashi H; Watanabe S; Kaneda H; Yoshida T; Takeda M; Shimizu T; Nakagawa K
    Ann Oncol; 2016 Jan; 27(1):200-2. PubMed ID: 26483048
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
    Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
    Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.